Honya Medical Services
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.
Coronary Artery Disease
MCRcI® stem cells
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 40 participants |
Masking : | SINGLE |
Masking Description : | Participant blind with dose. |
Primary Purpose : | TREATMENT |
Official Title : | Intra-Coronary Administration of MCRcI® (Myo-Cardial Regenerative Cellular Injection) Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease |
Actual Study Start Date : | 2025-12-01 |
Estimated Primary Completion Date : | 2026-01-01 |
Estimated Study Completion Date : | 2026-12-01 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 20 Years to 80 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Honya Medical Services
I think, Taiwan, 74147